Instrument Inactif

Communiqués e-therapeutics plc London S.E.

Actions

07/05/25	E-therapeutics Presents New Data Supporting ETX‑312 as a Differentiated and Disease-Modifying Near-Clinic Treatment for MASH	GL
05/02/25	E-therapeutics présentera des données précliniques relatives à l’ETX-148 lors de l’édition 2025 du Congrès annuel de l’EAHAD	GL
05/02/25	E-therapeutics to Present Preclinical Data on ETX-148 at EAHAD 2025	GL
31/10/24	E-therapeutics Announces Business Updates and Interim Results	GL
16/07/24	E-therapeutics plc, Results of Annual General Meeting and Appointment of Jeremy Punnett to the Board of Directors	EQ
16/07/24	E therapeutics : Results of Annual General Meeting and Appointment of Jeremy Punnett to the Board of Directors	PU
03/07/24	E-therapeutics announces completion of £28.90 million fundraise	EQ
06/06/24	E therapeutics : Annual Report for the year ended 31 January 2024	PU
06/06/24	E therapeutics : Pipeline update and final results for the year ended 31 January 2024	PU
23/05/24	Lord David Prior Appointed as Chair of e-therapeutics’ Board of Directors	EQ
23/05/24	E therapeutics : Lord David Prior Appointed as Chair of e‑therapeutics' Board of Directors	PU
23/05/24	E therapeutics : Lord David Prior Appointed as Chair of e‑therapeutics plc Board of Directors	PU
30/09/22	E-therapeutics: Fundraise of £13.5 million	PR